一品红跌2.02%，成交额8701.02万元，主力资金净流出211.05万元

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 187.22%, but recent trends indicate a decline over the past 20 and 60 days [1][2]. Financial Performance - For the period from January to September 2025, Yipinhong reported revenue of 814 million yuan, a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million yuan, an increase of 44.80% compared to the previous year [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 18, Yipinhong's stock price was 49.00 yuan per share, with a market capitalization of 22.133 billion yuan. The stock experienced a 2.02% decline during the trading session [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) five times this year, with the most recent appearance on July 21, where it recorded a net buy of 65.576 million yuan [1]. Shareholder Information - As of October 31, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period, with an average of 20,156 shares held per shareholder, a decrease of 8.61% [2]. - New institutional shareholders include Hong Kong Central Clearing Limited and several mutual funds, while E Fund Healthcare Industry Mixed A has exited the top ten shareholders list [3]. Business Overview - Yipinhong, established on February 4, 2002, and listed on November 16, 2017, is primarily engaged in the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals. The revenue composition includes 61.12% from pediatric drugs, 22.71% from chronic disease drugs, and 16.17% from other products [1].